- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Cases selected for the AskAnzal weekly PMCPA insight newsletter
Complaint about Lantus promotional leavepieces and a mailer. Issues included “24-hour efficacy” wording and a hypoglycaemia comparison based…
Bayer Schering was found to have promoted Xarelto (rivaroxaban) before UK authorisation via a UK congress exhibition panel…
Novo Nordisk’s Victoza launch activity led to multiple Code breaches, mainly around misleading claims, lack of balance/safety info,…
Anonymous employee alleged Astellas misled PMCPA about Milan advisory board delegate selection. Panel/Appeal Board found false/incomplete information and…
Intercompany complaint about Jext leavepiece diagrams and the claim “designed to be easy to use”. Panel found the…
PMCPA case AUTH/3068/9/18 (Director v Sanofi) concerned clinical trial disclosure but was ruled outwith the scope of the…
Anonymous complaint alleged unsolicited promotional emails to NHS staff about setting up ‘oral chemotherapy’ clinics without consent or…
A chief pharmacist complained about a Cipralex (escitalopram) promotional email sent via a database agency to local prescribers…
Actavis’ Levosert leavepiece implied broader suitability than Mirena and claimed a “25% saving” on acquisition cost. PMCPA ruled…
Public complaint alleged Sanofi failed to disclose clinical trial results for Multaq and Jevtana in line with ABPI/IFPMA…
One real case. One key lesson. Every week — free.